凯莱英（06821）今日盘中大涨5.21%，引起市场关注。这一涨幅很可能与西南证券最新发布的研究报告有关，该报告给予凯莱英"买入"评级。
根据西南证券的研究报告，凯莱英2025年上半年业绩表现亮眼。公司实现营收31.9亿元，同比增长18.2%；归母净利润达6.2亿元，同比增长23.7%。尤其值得注意的是，二季度单季度收入和净利润分别同比增长26.9%和33.9%，显示出强劲的增长势头。
报告还指出，凯莱英各业务板块均呈现良好发展态势。小分子CDMO业务保持双位数增长；化学大分子和生物大分子业务分别实现130%和70.7%的高速增长；临床CRO业务稳步恢复；制剂板块多个产品实现商业化供应。此外，公司在欧洲市场的收入更是实现了200%以上的大幅增长。西南证券预计凯莱英2025-2027年的每股收益将分别达到3.05元、3.55元和4.09元，维持"买入"评级。这份积极的研究报告无疑增强了投资者对凯莱英未来发展前景的信心，推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.